Aspacytarabine

N/A

Report date: 2022/12/07 17:07:41

Base Information

Drug NameAspacytarabine
Drug Alias NameAsparagine ara-C conjugateAsparagine cytarabine conjugateCytarabine asparagine conjugateAra-C asparagine conjugateBSR-236 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiosight Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiosight Ltd
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank